Pomanda estimates the enterprise value of GLAXOSMITHKLINE CAPITAL PLC at £0 based on a Turnover of £0 and 1.14x industry multiple (adjusted for size and gross margin).
glaxosmithkline capital plcEstimated Valuation
£0
Pomanda estimates the enterprise value of GLAXOSMITHKLINE CAPITAL PLC at £0 based on an EBITDA of £-605k and a 4.15x industry multiple (adjusted for size and gross margin).
glaxosmithkline capital plcEstimated Valuation
£166.3m
Pomanda estimates the enterprise value of GLAXOSMITHKLINE CAPITAL PLC at £166.3m based on Net Assets of £134.9m and 1.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Capital PlcOverview
Glaxosmithkline Capital Plc is a live company located in london, WC1A 1DG with a Companies House number of 02258699. It operates in the financial intermediation not elsewhere classified sector, SIC Code 64999. Founded in May 1988, it's largest shareholder is
smithkline beecham ltd
with a 100% stake. Glaxosmithkline Capital Plc is a mature,
unknown sized company, Pomanda has estimated its turnover at
£0 with
unknown
growth in recent years.
There is insufficient data available to calculate a health check for Glaxosmithkline Capital Plc. Company Health Check FAQs
Health Rating0out of 5
0 Strong
0 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Employees
with 1 employees, this is below the industry average (14)
- - Glaxosmithkline Capital Plc
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Capital Plc
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (29 weeks)
- - Glaxosmithkline Capital Plc
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 98.6%, this is a higher level of debt than the average (71.4%)
- - Glaxosmithkline Capital Plc
- - Industry AVG
GLAXOSMITHKLINE CAPITAL PLC financials
EXPORT
Glaxosmithkline Capital Plc's latest turnover from December 2023 is 0 and the company has net assets of £134.9 million. According to their latest financial statements, we estimate that Glaxosmithkline Capital Plc has 1 employee and maintains cash reserves of £1 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
2,711,000
547,000
2,034,383
Other Income Or Grants
Cost Of Sales
1,051,034
192,752
848,061
Gross Profit
1,659,966
354,248
1,186,322
Admin Expenses
605,000
-2,797,000
-1,067,857,382
-21,757,000
-18,004,000
-30,272,000
-10,301,000
-12,461,034
-10,614,752
-683,000
656,000
1,135,322
403,000
-476,000
-3,155,000
Operating Profit
-605,000
2,797,000
1,067,857,382
21,757,000
18,004,000
30,272,000
10,301,000
14,121,000
10,969,000
683,000
-656,000
51,000
-403,000
476,000
3,155,000
Interest Payable
307,490,000
471,643,000
436,729,000
348,296,000
376,137,000
387,930,000
383,849,000
400,444,000
413,739,000
426,275,000
414,791,000
406,631,000
393,445,000
Interest Receivable
325,627,000
480,543,000
454,369,000
377,474,000
387,262,000
399,340,000
394,271,000
408,331,000
422,225,000
431,976,000
418,846,000
409,623,000
396,635,000
Pre-Tax Profit
17,532,000
11,697,000
16,206,000
21,757,000
18,004,000
30,272,000
10,301,000
14,121,000
10,969,000
8,570,000
7,830,000
5,752,000
3,652,000
3,468,000
3,155,000
Tax
-4,120,000
-2,223,000
-3,079,000
-4,134,000
-3,421,000
-5,752,000
-1,983,000
-2,824,000
-2,220,000
-1,836,000
-1,845,000
-1,437,000
-1,002,000
-992,000
-884,000
Profit After Tax
13,412,000
9,474,000
13,127,000
17,623,000
14,583,000
24,520,000
8,318,000
11,297,000
8,749,000
6,734,000
5,985,000
4,315,000
2,650,000
2,476,000
2,271,000
Dividends Paid
Retained Profit
13,412,000
9,474,000
13,127,000
17,623,000
14,583,000
24,520,000
8,318,000
11,297,000
8,749,000
6,734,000
5,985,000
4,315,000
2,650,000
2,476,000
2,271,000
Employee Costs
Number Of Employees
1
1
1
1
1
1
1
14
3
1
1
10
1
1
EBITDA*
-605,000
2,797,000
1,067,857,382
21,757,000
18,004,000
30,272,000
10,301,000
14,121,000
10,969,000
683,000
-656,000
51,000
-403,000
476,000
3,155,000
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
Intangible Assets
Investments & Other
2,367,000
2,968,000
4,364,000
4,021,000
3,343,000
1,904,000
2,373,000
1,893,000
2,176,000
Debtors (Due After 1 year)
8,133,931,000
9,794,173,000
12,931,472,000
15,776,159,000
15,797,561,000
13,087,653,000
10,434,878,000
8,353,138,000
9,984,314,000
10,008,530,000
9,981,921,000
9,963,297,000
5,619,589,000
8,262,755,000
8,459,794,000
Total Fixed Assets
8,136,298,000
9,797,141,000
12,935,836,000
15,780,180,000
15,800,904,000
13,089,557,000
10,437,251,000
8,355,031,000
9,986,490,000
10,008,530,000
9,981,921,000
9,963,297,000
5,619,589,000
8,262,755,000
8,459,794,000
Stock & work in progress
Trade Debtors
2,767,682,000
Group Debtors
1,696,382,000
2,236,637,000
2,682,990,000
2,447,426,000
1,731,747,000
1,471,451,000
101,855,000
74,346,000
2,066,389,000
172,863,000
159,141,000
2,651,088,000
136,037,000
129,145,000
Misc Debtors
105,811,000
113,755,000
142,579,000
145,580,000
134,752,000
580,000
723,000
Cash
1,000
1,000
4,000
4,000
4,000
1,000
2,000
2,000
3,000
4,000
2,000
4,000
4,000
4,000
misc current assets
131,225,000
107,833,000
110,223,000
105,382,000
total current assets
1,802,194,000
2,350,393,000
2,825,573,000
2,593,010,000
1,866,503,000
1,602,676,000
209,689,000
2,877,907,000
179,730,000
2,066,392,000
172,867,000
159,143,000
2,651,092,000
136,621,000
129,872,000
total assets
9,938,492,000
12,147,534,000
15,761,409,000
18,373,190,000
17,667,407,000
14,692,233,000
10,646,940,000
11,232,938,000
10,166,220,000
12,074,922,000
10,154,788,000
10,122,440,000
8,270,681,000
8,399,376,000
8,589,666,000
Bank overdraft
Bank loan
Trade Creditors
649,000
Group/Directors Accounts
69,000
4,196,000
4,024,000
5,811,000
2,040,000
2,881,000
67,000
1,764,000
44,000
2,574,000
2,574,000
other short term finances
1,651,681,000
2,145,952,000
2,595,811,000
2,350,809,000
1,657,233,000
1,349,459,000
2,679,716,000
1,880,032,000
2,497,767,000
hp & lease commitments
other current liabilities
104,245,000
108,587,000
137,591,000
141,155,000
131,494,000
130,681,000
105,663,000
111,457,000
104,140,000
128,509,000
129,434,000
128,640,000
132,982,000
134,716,000
137,563,000
total current liabilities
1,755,995,000
2,254,539,000
2,737,598,000
2,495,988,000
1,794,538,000
1,482,180,000
108,544,000
2,791,173,000
104,207,000
2,010,305,000
129,478,000
131,863,000
2,633,323,000
134,716,000
137,563,000
loans
8,047,632,000
9,773,347,000
12,917,825,000
15,788,394,000
15,800,866,000
13,145,607,000
10,500,761,000
8,410,103,000
10,042,319,000
10,054,193,000
10,022,080,000
9,993,928,000
5,640,562,000
8,270,708,000
8,461,038,000
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
8,047,632,000
9,773,347,000
12,917,825,000
15,788,394,000
15,800,866,000
13,145,607,000
10,500,761,000
8,410,103,000
10,042,319,000
10,054,193,000
10,022,080,000
9,993,928,000
5,640,562,000
8,270,708,000
8,461,038,000
total liabilities
9,803,627,000
12,027,886,000
15,655,423,000
18,284,382,000
17,595,404,000
14,627,787,000
10,609,305,000
11,201,276,000
10,146,526,000
12,064,498,000
10,151,558,000
10,125,791,000
8,273,885,000
8,405,424,000
8,598,601,000
net assets
134,865,000
119,648,000
105,986,000
88,808,000
72,003,000
64,446,000
37,635,000
31,662,000
19,694,000
10,424,000
3,230,000
-3,351,000
-3,204,000
-6,048,000
-8,935,000
total shareholders funds
134,865,000
119,648,000
105,986,000
88,808,000
72,003,000
64,446,000
37,635,000
31,662,000
19,694,000
10,424,000
3,230,000
-3,351,000
-3,204,000
-6,048,000
-8,935,000
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
-605,000
2,797,000
1,067,857,382
21,757,000
18,004,000
30,272,000
10,301,000
14,121,000
10,969,000
683,000
-656,000
51,000
-403,000
476,000
3,155,000
Depreciation
Amortisation
Tax
-4,120,000
-2,223,000
-3,079,000
-4,134,000
-3,421,000
-5,752,000
-1,983,000
-2,824,000
-2,220,000
-1,836,000
-1,845,000
-1,437,000
-1,002,000
-992,000
-884,000
Stock
Debtors
-2,208,441,000
-3,612,476,000
-2,612,124,000
705,105,000
3,104,956,000
4,022,371,000
-584,087,000
1,062,160,000
-2,016,259,000
1,920,135,000
32,346,000
1,851,761,000
-128,695,000
-190,290,000
8,589,662,000
Creditors
-649,000
649,000
Accruals and Deferred Income
-4,342,000
-29,004,000
-3,564,000
9,661,000
813,000
25,018,000
-5,794,000
7,317,000
-24,369,000
-925,000
794,000
-4,342,000
-1,734,000
-2,847,000
137,563,000
Deferred Taxes & Provisions
Cash flow from operations
2,199,374,000
3,584,046,000
3,673,338,382
-677,821,000
-3,089,560,000
-3,972,833,000
586,611,000
-1,043,546,000
2,000,639,000
-1,922,213,000
-34,702,000
-1,856,840,000
125,556,000
186,927,000
-8,449,828,000
Investing Activities
capital expenditure
Change in Investments
-601,000
-1,396,000
343,000
678,000
1,439,000
-469,000
480,000
-283,000
2,176,000
cash flow from investments
601,000
1,396,000
-343,000
-678,000
-1,439,000
469,000
-480,000
283,000
-2,176,000
Financing Activities
Bank loans
Group/Directors Accounts
69,000
-4,196,000
172,000
-1,787,000
3,771,000
-841,000
2,881,000
-67,000
-1,697,000
1,720,000
-2,530,000
2,574,000
Other Short Term Loans
-494,271,000
-449,859,000
245,002,000
693,576,000
307,774,000
1,349,459,000
-2,679,716,000
2,679,716,000
-1,880,032,000
1,880,032,000
-2,497,767,000
2,497,767,000
Long term loans
-1,725,715,000
-3,144,478,000
-2,870,569,000
-12,472,000
2,655,259,000
2,644,846,000
2,090,658,000
-1,632,216,000
-11,874,000
32,113,000
28,152,000
4,353,366,000
-2,630,146,000
-190,330,000
8,461,038,000
Hire Purchase and Lease Commitments
other long term liabilities
share issue
1,805,000
4,188,000
4,051,000
-818,000
-7,026,000
2,291,000
-2,345,000
671,000
521,000
460,000
596,000
-4,462,000
194,000
411,000
-11,206,000
interest
18,137,000
8,900,000
17,640,000
29,178,000
11,125,000
11,410,000
10,422,000
7,887,000
8,486,000
5,701,000
4,055,000
2,992,000
3,190,000
cash flow from financing
-2,199,975,000
-3,585,445,000
-2,603,704,000
678,499,000
2,959,778,000
4,024,933,000
-577,397,000
1,059,514,000
-1,882,660,000
1,922,212,000
34,704,000
1,856,838,000
-125,556,000
-186,927,000
8,453,022,000
cash and cash equivalents
cash
-3,000
4,000
-1,000
-1,000
-1,000
-1,000
2,000
-2,000
4,000
overdraft
change in cash
-3,000
4,000
-1,000
-1,000
-1,000
-1,000
2,000
-2,000
4,000
glaxosmithkline capital plc Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for glaxosmithkline capital plc. Get real-time insights into glaxosmithkline capital plc's credit score, group structure and payment trends.
Perform a competitor analysis for glaxosmithkline capital plc by selecting its closest rivals, whether from the FINANCIAL AND INSURANCE ACTIVITIES sector, other mature companies, companies in WC1A area or any other competitors across 12 key performance metrics.
glaxosmithkline capital plc Ownership
GLAXOSMITHKLINE CAPITAL PLC group structure
Glaxosmithkline Capital Plc has no subsidiary companies.
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to glaxosmithkline capital plc.
glaxosmithkline capital plc Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GLAXOSMITHKLINE CAPITAL PLC. This can take several minutes, an email will notify you when this has completed.
glaxosmithkline capital plcCompanies House Filings - See Documents
